A randomized controlled study of Telitacicept in reducing relapse in patients with systemic lupus erythematosus (SLE) of low disease activity

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200058379

Enrollment

Unknown

Registered

2022-04-07

Start date

2022-07-01

Completion date

Unknown

Last updated

2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SLE

Interventions

experimental group:telitacicept +standard treatment

control group:standard treatment

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.18-75 years; 2. Patients with low disease activity (SELENA-SLEDAI = 7) who meet the classification standard of lupus in 2019; 3. If the hormone is less than 30mg/d, hydroxychloroquine and immunosuppressants (methotrexate, leflunomide, tacrolimus, cyclosporine, cyclophosphamide, mycophenolate mofetil, azathioprine) can be used together in the past.

Exclusion criteria

Exclusion criteria: 1. Those unwilling to participate in the study; 2. Severe liver and kidney dysfunction; 3. Malignant tumor/patients in infection stage; 4. Patients with myelodysplasia; 5. Pregnant women or women preparing for pregnancy during the follow-up period; 6. Patients who have used rituximab and belimumab in the past.

Design outcomes

Primary

Measure	Time frame
flare rate;	—

Secondary

Measure	Time frame
proportion of LLDAS;reduction of corticosteroids;SF-36;infection;side effects;	—

Countries

China

Contacts

Public ContactJunna Ye

Ruijin Hospital of Shanghai Jiao Tong University

yjn0912@qq.com+86 13817366731

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026